Skip to content
10-Q

Quarterly Report

21st Century Oncology Holdings, Inc.

0001558370-16-010067

← back to feed
Filed
Nov 14, 2016 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q3 2016 · Nov 14, 2016 1.06K sh
Capex Q3 2016 · Sep 30, 2016 $24.2M
Capex Q3 2016 · Sep 30, 2015 $33.6M
Cash And Equivalents Q3 2016 · Sep 30, 2016 $49.7M
Cash And Equivalents Q3 2016 · Dec 31, 2015 $65.21M
Cash And Equivalents restated Q3 2016 · Sep 30, 2015 $47.73M
Cash And Equivalents restated Q3 2016 · Dec 31, 2014 $99.08M
Stockholders Equity Q3 2016 · Sep 30, 2016 −$861.39M
Stockholders Equity Q3 2016 · Dec 31, 2015 −$700.95M
Current Liabilities Q3 2016 · Sep 30, 2016 $1.26B
Current Liabilities Q3 2016 · Dec 31, 2015 $1.21B
Total Liabilities Q3 2016 · Sep 30, 2016 $1.4B
Total Liabilities Q3 2016 · Dec 31, 2015 $1.37B
Current Assets Q3 2016 · Sep 30, 2016 $215.63M
Current Assets Q3 2016 · Dec 31, 2015 $221.28M
Total Assets Q3 2016 · Sep 30, 2016 $1.05B
Total Assets Q3 2016 · Dec 31, 2015 $1.1B
Sga Expense Q3 2016 · Sep 30, 2016 $35.34M
Sga Expense Q3 2016 · Sep 30, 2016 $101.07M
Sga Expense restated Q3 2016 · Sep 30, 2015 $68.31M
Sga Expense restated Q3 2016 · Sep 30, 2015 $141.34M
Net Income Q3 2016 · Sep 30, 2016 −$79.92M
Net Income Q3 2016 · Sep 30, 2016 −$97.48M
Net Income restated Q3 2016 · Sep 30, 2015 −$57.78M
Net Income restated Q3 2016 · Sep 30, 2015 −$140.48M
Gross Profit Q3 2016 · Sep 30, 2016 $66.15M
Gross Profit Q3 2016 · Sep 30, 2016 $215.3M
Gross Profit restated Q3 2016 · Sep 30, 2015 $74.35M
Gross Profit restated Q3 2016 · Sep 30, 2015 $237.06M
Cost Of Revenue Q3 2016 · Sep 30, 2016 $184.5M
Cost Of Revenue Q3 2016 · Sep 30, 2016 $573.5M
Cost Of Revenue restated Q3 2016 · Sep 30, 2015 $193.4M
Cost Of Revenue restated Q3 2016 · Sep 30, 2015 $595.2M